Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496)

Published:2016-06-28 Issue:19 Volume:122 Page:2996-3004
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Barta Stefan K.¹,Li Hailun²,Hochster Howard S.³,Hong Fangxin²,Weller Edie²,Gascoyne Randy D.⁴,Habermann Thomas M.⁵,Gordon Leo I.⁶,Colocci Natalia⁷,Bengtson Elizabeth M.⁸,Horning Sandra J.⁹,Kahl Brad S.¹⁰

Affiliation:

1. Fox Chase Cancer Center; Philadelphia Pennsylvania

2. Dana-Farber Cancer Institute; Boston Massachusetts

3. Yale University; New Haven Connecticut

4. British Columbia Cancer Agency; Vancouver British Columbia Canada

5. Mayo Clinic; Rochester Minnesota

6. Northwestern University; Chicago Illinois

7. Palo Alto Medical Foundation; Palo Alto California

8. Dartmouth Cancer Medical Center; Lebanon New Hampshire

9. Genentech, Inc; South San Francisco California

10. Washington University; St. Louis Missouri

Funder

Public Health Service

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference28 articles.

1. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program;McLaughlin;J Clin Oncol.,1998

2. Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma;Marcus;J Clin Oncol.,2008

3. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Hiddemann;Blood.,2005

4. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group;Forstpointner;Blood.,2004

5. New treatment options have changed the survival of patients with follicular lymphoma;Fisher;J Clin Oncol.,2005

Cited by 30 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Minimal Residual Disease Status Predicts Outcome in Patients With Previously Untreated Follicular Lymphoma: A Prospective Analysis of the Phase III GALLIUM Study;Journal of Clinical Oncology;2023-12-14

2. Maintenance and consolidation strategies for patients with untreated advanced follicular lymphoma: A systematic review and network meta‐analysis of randomized trials;Cancer;2023-12-02

3. Treatment of indolent lymphoma;Blood Research;2022-04-30

4. Marked Response to Chemoimmunotherapy in a Patient with Follicular Lymphoma of Huge Mesenteric Lymphadenopathy;Journal of Cancer Research and Practice;2022

5. Rituximab Maintenance Versus Observation After Immunochemotherapy (R-CHOP, R-MCP, and R-FCM) in Untreated Follicular Lymphoma Patients: A Randomized Trial of the Ostdeutsche Studiengruppe Hämatologie und Onkologie and the German Low-Grade Lymphoma Study Group;HemaSphere;2021-06-23

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3